| | | | | | | | | | |
|
| |
|
| Dockets Entered
February 11, 2005
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| 2000N-0504
|
| Egg Safety Action Plan
|
|
|
|
|
| 2004N-0416
|
| Beverages: Bottled Water
|
|
|
|
|
| 2004N-0454
|
| Dietary Supplements; Premarket Notification for New Dietary Ingredient Notifications; Public Meeting
|
|
|
|
|
| 2004N-0559
|
| Overall benefit to risk considerations for Cox-2 selective nonsteroidal anti-inflammatory drugs and related agents
|
|
|
|
|
| 2004P-0043
|
| Require Purdue Pharma to revise labeling of OxyContin Tablets
|
|
|
|
|
| 2004P-0070
|
| Withhold approval of any abbreviated New Drug Application ( ANDA) for a generic version of Ferrlecit( sodium ferric gluconate complex in sucrose ) until the conditions set forth in this petition are s
|
|
|
|
|
|
|
|
|
| 2004P-0349
|
| Action on Products containing added Mercury
|
|
|
|
|
| 2004P-0365
|
| Refrain from approving ANDA for Agrylin (anagrelide hydrochloride) Capsules
|
|
|
|
|
| 2005V-0064
|
| Projector for a Laser Light Show
|
|
| |
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| LET
15507
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15508
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15509
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15510
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15511
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15512
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15513
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15514
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15515
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15516
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15517
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15518
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15519
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15520
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15521
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15522
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15523
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15524
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15525
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15526
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15527
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15528
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15529
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15530
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
| | | | | | | | |
|
| |
|
| LET
15531
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15532
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15533
|
| McLind Corporation
|
| Vol #:
|
| 136
|
|
|
|
|
| LET
15534
|
| Herb Pharm
|
| Vol #:
|
| 136
|
|
|
|
|
| 2000N-0504
|
| Egg Safety Action Plan
|
|
|
|
|
| REF 1
|
| HF-26
|
| Vol #:
|
| 33
|
|
|
|
|
| 2004N-0416
|
| Beverages: Bottled Water
|
|
|
|
|
| REF 1
|
| HF-26
|
| Vol #:
|
| 3
|
|
|
|
|
| 2004N-0454
|
| Dietary Supplements; Premarket Notification for New Dietary Ingredient Notifications; Public Meeting
|
|
|
|
|
| C
27
|
| Jarrow Formulas, Inc. (JFI)
|
| Vol #:
|
| 5
|
|
|
|
|
| C 28
|
| J. Rabalais
|
| Vol #:
|
| 5
|
|
|
|
|
| C 29
|
| J. Pecce
|
| Vol #:
|
| 5
|
|
|
|
|
| C 30
|
| P. Pecce
|
| Vol #:
|
| 5
|
|
| |
|
| 2004N-0559
|
| Overall benefit to risk considerations for Cox-2 selective nonsteroidal anti-inflammatory drugs and related agents
|
|
|
|
|
| C 9
|
| B. Thurman
|
| Vol #:
|
| 2
|
|
|
|
|
| 2004P-0043
|
| Require Purdue Pharma to revise labeling of OxyContin Tablets
|
|
|
|
|
| LET 3
|
| K. Heuer
|
| Vol #:
|
| 3
|
|
|
|
|
| 2004P-0070
|
| Withhold approval of any abbreviated New Drug Application ( ANDA) for a generic version of Ferrlecit( sodium ferric gluconate complex in sucrose ) until the conditions set forth in this petition are s
|
|
|
|
|
|
|
|
|
| LET
2
|
| HFD-005 to Frommer, Lawrence & Haug, LLP
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004P-0349
|
| Action on Products containing added Mercury
|
|
|
|
|
| LET
1
|
| HFM-1 to Coalition for Mercury-free Drugs (CoMeD)
|
| Vol #:
|
| 1
|
|
|
|
|
| 2004P-0365
|
| Refrain from approving ANDA for Agrylin (anagrelide hydrochloride) Capsules
|
|
|
|
|
| LET
1
|
| HFD-005 to Arnall Golden Gregory LLP
|
| Vol #:
|
| 2
|
|
|
|
|
| 2005V-0064
|
| Projector for a Laser Light Show
|
|
|
|
|
| ACK
1
|
| HFA-305 to Laser Image Productions Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| VAR
1
|
| Laser Image Productions Inc.
|
| Vol #:
|
| 1
|
|
